Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in<i>BRCA1</i>and/or<i>BRCA2</i>in the PROfound Trial-Reference-Cited by-同舟云学术

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations inBRCA1and/orBRCA2in the PROfound Trial

Published:2023-11-14 Issue: Volume: Page:
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Mateo Joaquin¹^ORCID,de Bono Johann S.²^ORCID,Fizazi Karim³^ORCID,Saad Fred⁴^ORCID,Shore Neal⁵^ORCID,Sandhu Shahneen⁶^ORCID,Chi Kim N.⁷^ORCID,Agarwal Neeraj⁸^ORCID,Olmos David⁹^ORCID,Thiery-Vuillemin Antoine¹⁰,Özgüroğlu Mustafa¹¹^ORCID,Mehra Niven¹²^ORCID,Matsubara Nobuaki¹³,Young Joung Jae¹⁴^ORCID,Padua Charles¹⁵,Korbenfeld Ernesto¹⁶^ORCID,Kang Jinyu¹⁷,Marshall Helen¹⁸,Lai Zhongwu¹⁹,Barnicle Alan¹⁹,Poehlein Christian²⁰,Lukashchuk Natalia¹⁹^ORCID,Hussain Maha²¹^ORCID

Affiliation:

1. Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital Campus, Barcelona, Spain

2. The Institute of Cancer Research and Royal Marsden, London, United Kingdom

3. Institut Gustave Roussy, University of Paris Saclay, Villejuif, France

4. Centre de recherche du Centre Hospitalier de l’Université de Montréal/CRCHUM, Université de Montréal, Montreal, QC, Canada

5. Carolina Urologic Research Center, Myrtle Beach, SC

6. Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

7. BC Cancer Agency, Vancouver, BC, Canada

8. Huntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, UT

9. Department of Medical Oncology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain

10. Department of Medical Oncology, Centre Hospitalier Universitaire de Besançon, Besançon, France

11. Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey

12. Radboud University Medical Center, Nijmegen, the Netherlands

13. National Cancer Center Hospital East, Chiba, Japan

14. Center for Prostate Cancer, National Cancer Center, Goyang, Republic of South Korea

15. Cetus Medicina Oncologia, Betim, Brazil

16. Hospital Británico de Buenos Aires, Buenos Aires, Argentina

17. Global Medicines Development, Oncology R&D, AstraZeneca, Gaithersburg, MD

18. AstraZeneca contracted through PHASTAR, Cambridge, United Kingdom

19. 9Global Medicines Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom

20. Merck & Co, Inc, Rahway, NJ

21. 1Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL

Abstract

Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.23.00339

Reference33 articles.

1. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

2. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

3. Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry

4. Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors

5. Integrative Clinical Genomics of Advanced Prostate Cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploiting the DNA Damage Response for Prostate Cancer Therapy;Cancers;2023-12-23